The first two authors contributed equally to this article Yes-associated protein 1 (YAP1), a downstream effector of the Hippo pathway, plays an important role in the development and progression of multiple malignancies, including human gastric cancer (GC). However, the clinical significance of YAPI expression in GC needs to be comprehensively explored. Based on the pivotal role of YAP1 in the hippo pathway, we explored the clinicopathologic characteristics of YAPI overexpression and its relationship to some tumor biomarkers in GC. Ninety cases of GC, chronic gastritis (CG) and CG with dysplasia samples were collected, and clinical data of all patients with GC were analyzed. The expression of YAPI was assessed using immunohistochemical assay in biopsy samples. As a result, almost all the GC samples, but few CG and dysplasia samples showed YAPI positive staining mainly in the nucleus. The expression of YAPI was found in GC tissues with higher strong reactivity rate, compared with dysplasia and CG tissues (79.2% vs 47.1% and 15%, each P<O.OOI), and its expression level was elevated with the ascending order ofGC malignancy. However, no significant correlation was found between the expression of YAP1 and epidermal growth factor receptor (EGFR) with gender, age, gross stage, degree of differentiation, tumor size, TNM staging, perineural infiltration, vascular invasion, lymphatic vessel invasion and lymph node metastases in patients with GC (each P>O.05). Furthermore, Spearman rank correlation analysis also showed no correlation of YAP1 with EGFR, Ki-67, CD34 and topoisomerase II (TOP II). Taken together, YAPI is highly expressed in GC tissues compared with the dysplasia and CG tissues and its expression level is elevated with the ascending order oftumor malignancy; but, YAPI expression does not correlate with the clinicopathologic characteristics and the expression ofEGFR, Ki-67, CD34 and TOP II in GC.
proliferation and outgrowth of organ size, suggesting a role in carcinogenesis (2) .
YAP protein is elevated and nuclear localized in some human cancers, and plays a key role in the Hippo pathway to control cell proliferation in response to cell contact (3) . YAP is highly expressed in some malignant solid tumors, and is a frequently activated oncogenic pathway (4, 5) . YAP expression in the cytoplasm and nucleus is also significantly increased in esophagus dysplasia and adenocarcinoma as well as gastric adenocarcinoma and metastatic gastric disease, suggesting a role for gastrointestinal epithelial tumorigenesis. YAP may be a putative oncogene in esophageal cancer and represent a potential diagnostic and therapeutic target (6, 7) . YAP1 is amplified and upregulated in hedgehog-associated medulloblastomas and mediates sonic hedgehog-driven neural precursor proliferation (8) . It can be considered as an independent prognostic marker for overall survival and disease-free survival times ofsome cancer patients and is a potential therapeutic target for the aggressive malignancy (9, 10) .
However, some studies have proved that YAP acts as a tumor suppressor in invasive breast carcinomas and can be used as a molecular marker for estrogen and progesterone negative breast tumors (11). YAP as a tumor suppressor can be deregulated by activated AKT and transcriptional repression by~Np63, and knockdown of YAP enhances cell proliferation, survival, migration and cisplatin chemoresistance (12, 13) . YAP' binds and stabilizes the pro-proliferativẽ Np63a isoform in a JNK-dependent manner, and protects cancer cells from UV irradiation but promotes UV-induced apoptosis through up-regulation of Bax expression by interaction with p73 (14, 15) .
Therefore, further basic and clinical studies are warranted to confirm the roles played by YAPI in clinical cancer medicine. In the present study, in order to elucidate the role ofYAP in GC development and progression, we evaluated the expression of YAPI in human GC, dysplasia and CG tissues using immunohistochemical (IHC) assay and studied the clinical significance of YAP1 overexpression and its correlation with some tumor biomarkers in GC.
MATERIALS AND METHODS

Materials
Human GC, dysplasia and CG tissues were from the Department of General Surgery and Digestive Endoscopy Room of Shanghai Sixth People's Hospital. Tissue microarray of human GC was made by Shanghai Outdo Biotech CO.LTD (China). YAP1 antibody was from Santa Cruz Biotechnology (USA).
Clinical samples and data
A total of 53 cases ofhuman GC, 17 cases of dysplasia and 20 cases of CG were enrolled in this study at General Surgery and Digestive Endoscopy Room from September 2007 to December 2011. The pathologic staging was made according to the American Joint Committee on Cancer (AJCC) TNM staging system. The use of the tissue microarray samples and clinical data was approved by the Medical Ethics Committee of Shanghai Jiao Tong University, and the patients' clinical and histopathologic data are summarized in Table I .
Tissue microarrays
For each case, we selected the tumor foci for construction of the tissue microarrays during routine diagnosis by marking them on the more representative hematoxylin-eosin-stained slide with a waterproof pencil. The advanced tissue arrayer (ATA-lOO, Chemicon International, Tamecula, CA, USA) was used to create holes in a recipient paraffin block and to acquire cylindrical core tissue biopsies with a diameter of 1 mm from the specific areas of the "donor" block. The tissue core biopsies were transferred to the recipient paraffin block at defined array positions. The tissue microarrays contained tissue samples from 40 formalin-fixed paraffinembedded cancer specimens with known diagnosis, and correlated benign tumour tissues from patients.
The block was incubated in an oven at 45°C for 20 min to allow complete embedding of the grafted tissue cylinders in the paraffin of the recipient block, and then stored at 4°C until microtome sectioning.
Immunohistochemical staining
YAPI antibody was used for IHC detection of YAP1 protein expression. Tissue microarray sections were processed for IHC demonstration of YAPI protein.
The anti-YAPI antibody was used at 1:200 dilutions. Endogenous peroxidase was inhibited by incubation with freshly prepared 3% hydrogen peroxide with 0.1% sodium azide. Non-specific staining was blocked with 0.5% casein and 5% normal serum. Tissue were incubated with biotinylated antibodies and horseradish peroxidase. Staining was developed with diaminobenzidine substrate and sections were counterstained with hematoxylin. Normal serum or PBS replaced anti-YAPI antibody in negative controls.
The quantification evaluation of YAP1 protein expression
YAP1 expression was semiquantitatively estimated as the total YAPI immunostaining score, which was calculated as the sum ofa proportion score and an intensity score. The score reflected the fraction of positive staining cells (score 0, <5%; score 1,5%-10%; score 2,10%-50%; score 3, 50%-75%; score 4, >75%). The intensity score represented the staining intensity (score 0, no staining signal; score I, weak positive signal; score 2, moderate positive signal; score 3, strong positive signal). Finally, a total expression score was given ranging from 0 to 12.
Based on the analysis in advance, the overexpression of YAPI was defined as the total expression score-> 9.
Statistical analysis
The results obtained were expressed as the mean ± standard error from at least three independent experiments. SPSS 13.0 was used for the statistical analysis. Kruskal-Wallis H test and chi-square test were used to analyze the expression rate in all groups. Wilcoxon rank sum test was used to analyze the correlation between protein expression and clinicopathologic feature of cancer. Significance was defined as P<0.05.
RESULTS
The expression of YAP1 protein in human GC
Expression of YAP1 protein was evaluated using IHC staining. As for the deregulation of the Hippo signaling pathway in cancer, the expression of YAP protein was mainly localized in the nucleus. In human GC tissues, the expression of YAP1 protein was also mainly detected in the nucleus (Fig. lA,  B ). But in rare cases of samples, the positive staining could be found in the nucleus and cytoplasm (Fig.  IC, D) . Conversely, in human dysplasia tissues, the expression of YAP1 protein was mainly located in the cytoplasm ( Fig. 2A, B ). In rare cases of samples, the positive staining could be found in the nucleus and cytoplasm (Fig. 2C, D) . In human CG tissues, there was no positive staining in most of the samples (Fig. 3A, B ). But, in rare cases of samples, the positive staining could be found in the cytoplasm (Fig. 3C, D) . As shown in Table II The correlation ofYAP1 protein overexpression with the clinicopathologic characteristics of GC The relationship between YAPI overexpression and various clinical and histopathologic features was analyzed. As a result, no significant correlation was found between YAPI overexpression with gender, age, gross stage, degree of differentiation, tumor size, TNM staging, perineural infiltration, vascular invasion, lymphatic vessel invasion and lymph node metastases in patients with GC (each P>0.05) (Table  III) .
The correlation ofEGFR protein expression with the clinicopathologic characteristics of GC
The patients with GC expressing EGFR are shown in Table IV , and the relationship between the positive expression ofEGFR and various clinical and pathologic features of GC was further analyzed. As a result, no significant correlation was found between EGFR expression with gender, age, gross stage, degree of differentiation, tumor size, TNM staging, perineural infiltration, vascular invasion, lymphatic vessel invasion and lymph node metastases in patients with GC (each P>0.05) (Table IV) .
The correlation of YAP1 protein expression with some tumor biomarkers ofGC
The patients with GC expressing EGFR, Ki-67, CD34 and TOP II are shown in Table I . As shown in Fig. lA , the GC sample with YAPI positive staining could also express the proteins of EGFR, Ki-67, CD34 and TOP II. Thus, the correlation of YAPI protein expression with EGFR, Ki-67, CD34 and TOP II protein expression needed to be analyzed. Table V , the results of Spearman rank correlation analysis indicated no correlation ofYAP1 with EGFR, Ki-67, CD34 and TOP II in oc.
As shown in
DISCUSSION
YAP is inactivated by the tumor suppressive Hippo pathway. The YAP as oncogene is amplified in human cancer, and promotes tumor growth and metastasis (16, 17) . There are accumulating reports about the expression and function of YAP in cancer. The overexpression of YAP enhances tumorigenesis and progression, whereas down-regulation of YAP inhibits these effects, suggesting that YAP acts as an oncogene in breast cancer (18) . YAPI is widely expressed in human brain tumors and promotes glioblastoma growth, representing a new target (19) . Differential expression of YAP is also correlated with cell cycle markers and pathologic TNM staging in non-small-cell lung carcinoma (20) . Therefore, the expression and clinicopathologic characteristics of YAP1 in GC were evaluated using IHC staining in our study. The results showed that the expression ofYAP1 protein was mainly localized in the nucleus in GC tissues, whereas in rare cases of GC and most cases ofdysplasia and CG, its positive staining could be found in the cytoplasm or nucleus and cytoplasm, suggesting that GC development might associate with the translocation of YAP1 from the cytoplasm to the nucleus. In addition, YAP1 protein expression was detected in 42/53 (79.2%) GC tissues, and 3/20 (15.0%) and 8/17 (47.1%) in CG and dysplasia tissues, and its expression level was elevated with the ascending order of tumor malignancy. But, findings support YAP1 exhibits oncogenic property in GC and could be a prognostic biomarker and potential therapeutic target for GC (21, 22) . EGFR as a cell membrane receptor is overexpressed in a variety of human solid tumors, plays an important role in cancer biology and offers a promising molecular therapeutic target. EGFR is also related to poor prognosis in patients with GC, and evaluation of EGFR status could interpret future clinical trials properly using EGFR targeted agents (23, 24) . EGFR is involved in the invasion and progression of GC, serves as a novel molecular marker and could be used to evaluate the degree of differentiation and prognosis in patients with GC (25, 26) . However, in our study, EGFR expression was found to be not associated with gender, age, gross stage, degree of differentiation, tumor size, TNM staging, perineural infiltration, vascular invasion, lymphatic vessel invasion and lymph node metastases in patients with GC, which may be associated with the insufficient data of gastric cancer patients we have collected.
Intriguingly, EGFR ligand AREG has been identified as a transcriptional target of YAP and can contribute to YAP-mediated cell proliferation and migration. Thus, YAP-dependent secretion of AREG indicates that activation of EGFR signaling is an important effector of the Hippo pathway (27) . However, in our study, the results of Spearman rank correlation analysis indicated no correlation ofYAP1 with EGFR signaling pathway in GC.
Ki-67 is a nuclear protein that is expressed in proliferating cells and may be required for maintaining cell proliferation, used as a marker for cell proliferation of GC (28) . CD34 cell surface molecule is a one-pass tym: I trans-membrane glycoprotein and located on chromosomelq32. Cellular expression of CD34 is seen in cancer precursor and capillary endothelial cells. Moreover, EGFR expression significantly correlates with Ki-67 index scores among the patients with GC (29) (30) (31) . The TOP II gene located near HER2 on chromosome 17 is the target of many chemotherapeutic agents, and co-amplification of HER2 and TOP II has been described in several tumor types (32) . But, in our study, the results of spearman rank correlation analysis indicated no correlation of YAP1 with Ki-67, CD34 and TOP II in GC.
In conclusion, YAPI is highly expressed in GC tissues compared with the dysplasia and CG tissues and its expression level is elevated with the ascending order of tumor malignancy; however, YAP1 expression does not correlate with the clinicopathologic characteristics and the expression ofEGFR, Ki-67, CD34 and TOP II in human gastric cancer.
